Coologics is developing Vlisse, a patented drug-free intravaginal cooling device intended to treat VVC, BV, and mixed vaginal infections by restoring the vaginal environment without antibiotics. The company positions Vlisse as a paradigm shift from traditional antifungal drugs and emphasizes reducing unnecessary antibiotic use. The recent oversubscribed seed financing will fund completion of an ongoing clinical trial, FDA submission, and initial market release. Coologics frames its technology as sustainable and focused on improving women’s health outcomes. The company’s leadership includes CEO/founder Dr. Kim Langdon and CMO Dr. Nicole Williams, who are alumni of Ohio State University and the University of Illinois, respectively. The announcement was issued from Cleveland on April 23, 2025.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025